Interferon-γ-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma

Cancer Research

Volumn 62, Issue 15, 2002, Pages 4406-4412

  Pulaski, Beth A ^a   Smyth, Mark J ^b   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; GAMMA INTERFERON; PERFORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

ANIMALS; CELL DIVISION; FEMALE; INTERFERON TYPE II; KILLER CELLS, NATURAL; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PHAGOCYTES; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTES; TRANSFECTION;

EID: 0036681991     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. The role of γ interferon in antimicrobial immunity
2. Cellular responses to interferon-γ
3. Relationship between interferon-γ, indoleamine 2, 3-dioxygenase, and tryptophan catabolism
4. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-γ induction is associated with clinical response
5. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
6. Wiltrout Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy
7. CD4+ T-cell mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells
8. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis
9. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2-neu transgenic mice
10. Metastatic prostate cancer in transgenic mouse
11. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor
12. MHC class II and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth
13. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative breast cancer model
14. Cutting Edge: Stat6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
15. A novel orthotopic model of breast cancer metastasis to bone
16. Perforin is a major contributor to NK cell control of tumor metastasis
17. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with IL-12 reduces established metastatic disease and stimulates immune effectors and monokine-induced by interferon-γ
18. Macrophages as accessory cells for class I MHC-restricted immune responses
19. Reduced tumorigenicity of murine tumor cells secreting γ-interferon is due to non-specific host responses and is unrelated to class I major histocompatibility complex expression
20. Analysis of the effects of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-γ) on generation of primary cytotoxic T lymphocytes against a weekly immunogenic tumor
21. Intraperitoneal macrophages and tumor immunity: A review
22. Dendritic cells: Specialized and regulated antigen processing machines
23. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors
24. Interferon-γ treatment of metastasized malignant melanoma
25. A Phase I trial of intraperitoneal recombinant γ-interferon in advanced ovarian carcinoma
26. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon γ
27. Schreiber lymphocytes prevent primary tumour development and shape tumour immunity
28. The molecular biology of interferon-γ and its receptor
29. Differential tumor surveillance by natural killer (NK) and NKT cells
30. Gene transfer of Fas ligand induces tumor regression in vivo
31. Antitumor effect of locally produced CD95 ligand
32. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
33. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma